Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Curren... (ary enrollment process administered thro...)

HOME >> BIOLOGY >> TECHNOLOGY

Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients

Date:8/22/2007

ary enrollment process administered through patients' healthcare providers, enrollees will have the comfort that GAMMAGARD LIQUID and GAMMAGARD S/D is available to them even if they experience changes involving their providers or site of care. A third party vendor will manage the program, and Baxter will not have access to patient data.

Enrollment in this program will be voluntary and will not automatically preclude those patients not participating in the program from accessing GAMMAGARD LIQUID and GAMMAGARD S/D. Baxter will continue to work closely with patient organizations and key thought leaders from different clinical specialties that prescribe IGIV therapy to launch the program. Patients not enrolling in the voluntary GARDian program will still be eligible for other GAMMAGARD patient programs (e.g. GAMMAssist and the Low IgA/Brand Intolerance Program and product Portability programs).

"Baxter has a long, proud history of advancing the science of IGIV therapy and serving the patients who rely on our IGIV therapies," said Larry Guiheen, president, Baxter Biopharmaceuticals, North America. "Baxter is committed to providing continued access to their therapy of choice for our patients. The GARDian program represents our continued commitment to that goal."

Patients and physicians can sign up to receive more information about the GARDian program at http://www.immunedisease.com.

About GAMMAGARD LIQUID 10%

GAMMAGARD LIQUID is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

About GAMMAGARD S/D

GAMMAGARD S/D is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Merge launches diagnostic mammography workstation in Europe
2. Einstein Wireless launches cellular alert system
3. Logistics Health launches compliance management tool
4. UW-Madison launches new high-speed research network
5. UWM launches research foundation
6. Weather information companies launch data product
7. TeraMedica launches information manager
8. GE Healthcare launches hybrid electronic record
9. Cedara launches new version of DICOM toolkit
10. Merge launches Spanish version of imaging tool
11. Orbitec will use $25 million Air Force contract to make small launch vehicle

Post Your Comments:

Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Curren...(ary enrollment process administered thro...)